Background : APC and E-cadherin are the key molecules in the Wnt/β -catenin pathway. We attempted to define the epigenetic alteration of APC and CDH1 (the E-cadherin gene) and the expression of Wnt-related molecules in human mammary carcinomas. Methods : Sixtyfour mammary carcinomas, including 52 invasive ductal carcinomas (IDCs) and 12 invasive lobular carcinomas (ILCs), were evaluated using methylation-specific PCR and immunohistochemistry. We performed immunohistochemistry for E-cadherin, β -catenin, APC, Wnt1, cyclin D1, ER, PR and C-erb B2. Results : Hypermethylation of APC and CDH1 was observed in 38 (59%) and 28 (44%) cases, respectively. CDH1 hypermethylation in ILCs was increased compared to that in IDCs (p=0.002) and it was associated with the loss of E-cadherin (p=0.02) and β -catenin (p=0.042). APC methylation was positively correlated with the ER expression (p=0.021). Abnormal cytoplasmic localization of β -catenin was found in 10 cases and any expression was not detected in six cases. In ILCs, the E-cadherin or β -catenin expression was markedly decreased compared to that in IDCs (p<0.001 in both). Conclusions : Methylation of APC or CDH1 was relatively frequent in mammary carcinomas. The loss of E-cadherin in mammary carcinoma was associated with CDH1 methylation, and abnormal β -catenin expression was related to the loss of E-cadherin in ILC.
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Although many previous studies of these tumors have been performed, the molecular carcinogenesis of breast cancer has not yet been fully determined.
Wnt signaling is known to contribute to the development of various malignant tumors, and especially gastrointestinal malignancies such as colon cancer, and Wnt signaling is also known to regulate stem cell development. APC and E-cadherin are key tumor suppressor molecules in a variety of cancers and they also play central role in the canonical or non-canonical Wnt pathway. In the canonical pathway, a defective APC-GSK3 β -axin-β -catenin complex induces an abnormal nuclear/cytoplasmic localization of the β -catenin and this activates a transcription factor that accelerates cell proliferation. APC defects are known to be highly correlated with the destruction of this catenin complex.
2,3 Although somatic mutation or the loss of heterozygosity (LOH) of APC and CDH1 (E-cadherin gene) is frequently seen in gastrointestinal carcinomas, there have been only a few reported mutations of APC in mammary tumors. 4 E-cadherin is a representative adhesion molecule of the epithelial cells; it comprises a membranous structural complex with β -catenin, and this complex functions in cell-cell identification and tissue morphogenesis. When carcinoma cells lose E-cadherin, they have a chance to become poorly differentiated tumor cells and gain an infiltrative character, and they can ultimately become capable of metastasizing.
Mammary lobular carcinomas have characteristic clinico-pathological features compared with the ductal carcinomas. The tumor cells of mammary lobular carcinomas are relatively small and they lack cellular adhesion with little tubule formation. Because ductal carcinomas do not make tubules in many cases, the histological features cannot perfectly discriminate between these two types of lesions. When performing immunohistochemical staining, E-cadherin is completely lost in almost all the mammary lobular carcinoma cells and this is in contrast to the ductal carcinomas, in which no change or only a slight decrease of staining intensity is observed in 80-100%. 6, 7 The loss of E-cadherin is not always caused by the gene defect itself.
8 Hypermethylation of the gene promoter CpG islands is associated with delayed replication, condensed chromatin and transcriptional inhibition.
9 Therefore, the transcriptional suppression mechanism of gene promoter hypermethylation of APC and CDH1 has been examined in two representative histological mammary carcinoma types (ductal and lobular carcinomas), respectively.
10-12
Of the 19 Wnt genes, Wnt1 was the first to be proven to be a mammary oncogene in mammary tumor virus (MMTV)-induced tumors. 13 The expression of its human homolog transcript in human breast cancer tissue has rarely been described. 14, 15 In this study, we examined and compared the methylation status of the APC and CDH1 promoter CpG islands in human mammary ductal and lobular carcinomas. We also investigated the expression profiles of the Wnt pathway-related molecules and Wnt1. We were able to discover the relationship between the promoter CpG island hypermethylation statuses of APC and CDH1 and the expression of Wnt-related molecules, including β -catenin, in human mammary carcinomas.
MATERIALS AND METHODS

Case selection
We analyzed 64 formalin-fixed, paraffin-embedded tissues of sporadic mammary carcinomas that were surgically resected between January 2001 and December 2004. They were collected from the archives of the Department of Pathology, CHA General Hospital, CHA University with Institutional Review Board approval. All the patients were female with a mean age of 49 years (range: 29-81 years). Fifty-two invasive ductal carcinomas (IDC) and 12 invasive lobular carcinomas (ILC) were included. All tumors were newly diagnosed, and the recurrent or hereditary lesions were excluded. Of the 64 invasive cancers, 23 cases were in stage I, 27 were in stage II and 14 were in stage III (Table 1) .
DNA extraction
Manual microdissection on H&E stained slides for DNA extraction was performed on the formalin-fixed, paraffin-embedded specimens by using a 27 1 2-gauge injection needle under a low-power (×4) objective view. The tumor areas with more than 90% cellularity were chosen for excision. The paired normal tissue was also obtained and analyzed to exclude germ line mutations. The DNA was extracted by using a previously described method.
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Bisulfite modification of the DNA and methylation-specific polymerase chain reaction (MSP)
The method for determining the status of the CpG island methylation of APC and CDH1 was performed as described previously. 17 The DNA was denatured with 2 mol/L NaOH at 37℃ for 10 min, and this was followed by incubation with 3 mol/L sodium bisulfite (pH 5.0) at 50℃ for 16 h in the dark. After treatment, the DNA was purified using the DNA purification kit (Promega, Madison, WI, USA) as recommended by the manufacturer; it was incubated with 3 mol/L NaOH at room temperature for 20 min and then it was precipitated with ethanol. The methylation status of each gene was determined using 2 μ L of modified DNA as a template for the PCR with using primers that are specific for the methylated and unmethylated alleles. The previously reported primers for the unmethylated or methylated sequence of APC gene promoter 1A and CDH-1 were used. 18, 19 The sequences for APC were as follows: U-f: 5′ -GTGTTT-TATTGTGGAGTGTGGGTT-3′ , U-r 5′ ;-CCAATCAACAAA-CTCCCAACAA-3′ , M-f 5′ -TATTGCGGAGTGCGGGTC-3′ , and M-r 5′ -TCGACGAACTCCCGACGA-3′ . The sequences for CDH1 were as follows: U-f 5′ -TAATTTTAGGTTAGAG-GGTTATTGT-3′ , U-r 5′ -CACAACCAATCAACAACACA-3′ , M-f 5′ -TTAGGTTAGAGGGTTATCGCGT-3′ , and M-r 5′ -TAACTAAAAATTCACCTACCGAC-3′ . PCR was performed for 35 cycles at 95℃ for denaturing, 55.5℃ for annealing (53.5℃ for CDH1), and 72℃ for extension with a final extension step of 5 min. Seven μ L of the PCR products were electrophoresed on 2% agarose gels and they were visualized by ethidium bromide staining. Commercially manufactured methylated and unmethylated DNAs (CpGenome Universal Methylated and Unmethylated DNA, Chemicon, CA, USA) were used as controls. lent to that of the marker (7 ng/μ L) were scored as methylated.
Immunohistochemical staining and interpretation
Paired cores from the neoplastic lesions and the adjacent normal parenchyme of the prepared paraffin blocks were selected and then tissue microarray blocks were constructed. Immunohistochemical staining using diaminobenzidine as the chromogen was performed by an automated staining system (Autostainer Plus, Dako, Denmark). The antibodies that were used were Wnt-1 (G-19, goat polyclonal; Santa Cruz Biotechnology, CA, USA; 1:100 dilution), β -catenin (14/beta-catenin, mouse monoclonal; Transduction Laboratories, KY, USA; 1:200 dilution), APC (C-20, rabbit polyclonal; Santa Cruz Biotechnology; 1:200 dilution), cyclin D1 (DSC-6, mouse monoclonal; Santa Cruz Biotechnology; 1:50 dilution), E-cadherin (HECD-1, mouse monoclon-al; Zymed, CA, USA; 1:100 dilution), estrogen receptor (ER; ID5, mouse monoclonal; Dako; 1:200 dilution), progesterone receptor (PR; PgR636, mouse monoclonal; Dako; 1:200 dilution) and c-erb B2 (rabbit polyclonal; Zymed; 1:50 dilution). Biotinylated sheep anti-mouse or anti-rabbit IgG (Dako) or donkey anti-goat IgG (Santa Cruz Biotechnology) was used as a secondary antibody.
ER and PR were considered as increased or positive when the proportion of cells that stained positive was above 10%. c-erb B2 was scored on a 0-3+ scale: 0 was, <10% of cells with membrane staining; 1+ was, faint, barely perceptible membrane staining in ≥10% of cells; 2+ was, weak to moderate membrane staining in ≥10% of the cells; 3+ was, strong, complete membrane staining in ≥10% of the cells. A score of 2+ or 3+ was considered as positive. The other immunohistochemical contents were scored depending on the extent and intensity of staining, as was described previously. 20 In brief, the intensity of staining was graded according to a 4-tiered scale of 0 to 3 (with 3 as the most intense staining). The extent of positive immunoreactivity was graded according to the percentage of stained cells in the region of interest: 0 points for 0%, 1 point for <20%, 2 points for 20-50%, and 3 points for >50%. An overall score was obtained from the sum of the intensity and the extent of the positive staining. Cases with a final score of more than three were defined as positive. We also examined abnormal cytoplasmic and/or nuclear localization of β -catenin. Two independent, experienced pathologists graded all the sections without any knowledge of the patients' clinical statuses.
Statistical analysis
The data was analyzed with Statistical Package Service Solution software (SPSS 10.1 for Windows, SPSS Inc., IL, USA). The correlations between the immunoprofile or methylation status and the clinical information were analyzed using the chi square test or Fisher's exact test (2-tailed). Statistical significance was defined as p-value <0.05.
RESULTS
The methylation status of APC and CDH1 and its correlation with the other factors APC hypermethylation was frequently found in the cases from young age patients (p=0.045) ( Table 1) . Hypermethylation of the APC and E-cadherin genes was common in breast cancer (59% and 44%, respectively). Of the 38 cases (60%) that showed APC promoter CpG island hypermethylation, 29 (76%) were IDCs and nine (24%) were ILCs (Fig. 1A) ( Table 1) . CDH1 hypermethylation was observed in 28 (44%) cases, of which 18 cases were IDC and 10 cases were ILC (Fig. 1B) (Table 1) . CDH1 hypermethylation was significantly more frequent in the lobular carcinomas (10/12, 83%) than in the ductal carcinomas (18/52, 35%) (p=0.002), while APC hypermethylation did not show any significant difference between the IDCs (29/52, 56%) and the ILCs (9/12, 75%) (p=0.225). The methylation of the APC gene and its protein expression were not associated (p=0.588). APC methylation was significantly more frequent in the ERpositive cases (27/38, 71%) than in the ER-negative tumors (11/26, 42%) (p=0.021) ( Table 1) . CDH1 methylation showed positive correlation with the tumor stage (p<0.001) ( Table 1) . CDH1 hypermethylation was inversely correlated with the membranous expression of E-cadherin (p=0.042) and β -catenin (p= 0.02) ( Table 1) . When each subtype was analyzed individually, CDH1 methylation was inversely correlated with the E-cadherin expression in the IDCs. All the 10 cases of ILC with CDH1 hypermethylation showed the loss of E-cadherin (data not shown).
All the other clinicopathological parameters did not show any correlation with the methylation of the APC gene or the E-cadherin gene nor with their corresponding protein expressions.
Abnormal β -catenin expression and its correlation with the other factors β -catenin was maintained on the cell membrane in 48 (75%) of the 64 cases ( Fig. 2A) , but 16 cases (5 IDCs and 11 ILCs) showed a cytoplasmic accumulation or a complete loss of β -catenin (Fig. 2B) . No obvious nuclear expression of β -catenin was found in our cases. Of the 12 cases of ILC, five cases showed cytoplasmic staining and six cases lost their β -catenin stainability. This abnormal staining of β -catenin was significantly more frequent in the ILC cases than in the ductal carcinomas (p< 0.001) ( Table 2 ). An abnormal expression of beta-catenin was associated with none of the other canonical Wnt pathway molecules, such as the APC, Wnt-1 or cyclin D1 expression, nor with the other clinical parameters such as the grade or stage, or the ER and PR statuses (data not shown). E-cadherin was positive in 47 of the 52 IDC cases. In contrast, all 12 ILCs were negative for E-cadherin (p<0.001) (Fig. 2C, D) (Table 2 ). An abnormal β -catenin expression (loss or cytoplasmic) was associated with the loss of E-cadherin (p<0.001), but not with the APC expression (p=0.142) ( Table 3) . When the ILCs and IDCs were analyzed individually, the abnormal expression of β -catenin correlated with the loss of E-cadherin, and particularly in the ILCs. In the IDCs, all the five cases with loss of E-cadherin retained the normal membranous β -catenin expression (data not shown).
Expression of the other Wnt pathway molecules
Forty-seven (73%) tumors revealed the loss of an APC expression (Fig. 2E ). An APC expression was not associated with an abnormal β -catenin expression (p=0.142) ( Table 3) . Cyclin D1 was positive in 22 cases (34%) ( Table 2 ). Wnt-1 was expressed in 22 tumors (34%), and its positivity rate was not related to the tumor type (p=0.482) (Fig. 2F) .
DISCUSSION
The Wnt signaling pathway has been a hot topic in the field of oncology, as well as in embryology and stem cell biology. Nevertheless, the results of the research on tumorigenesis in a variety of human organs have been inconsistent. In human breast Fig. 2 . Immunohistochemical staining patterns of Wnt related markers in mammary carcinomas. β -catenin usually enhances epithelial membrane (A). In contrast to the normal membranous pattern, some cases abnormally express β -catenin in the cytoplasm in invasive ductal carcinoma (B). E-cadherin is preserved on the membrane of ductal carcinoma cells (C), but on the other side E-cadherin is totally lost in lobular carcinoma cells (D). APC (E) and Wnt-1 (F) are expressed in the cytoplasm of invasive ductal carcinoma cells.
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tissue, Wnt and its related molecules, including E-cadherin and β -catenin, are known to affect the growth and function of the mammary glands, and the destruction of their delicate interaction via some potential mechanisms can result in mammary neoplasia.
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ILC is a minor malignant tumor that makes only 5-15% of all invasive breast cancers, and ILC presents with a unique histology and clinical features, including bilaterality and muticentricity. 22, 23 In a previously reported larger-scale study on mammary lobular carcinoma, the tumor methylation rate of CDH1 was 41% (vs 83% in the present study).
11 This result might be caused by the differences in accuracy of microdissection or the additive molecular changes, including genetic mutations or allelic losses. In the present study, E-cadherin loss was found in all 12 ILC cases; 10 of these cases showed epigenetic changes of CDH1, while 35% of the IDCs displayed methylation of CDH1. This finding shows that CDH1 promoter hypermethylation is a significantly more common feature in mammary lobular carcinoma than in the ductal carcinomas. The epigenetic alteration of the E-cadherin gene was associated to the loss of the E-cadherin expression, and this result is concordant with the previous studies.
11,12
Despite the relatively high frequency of epigenetic changes of APC and CDH1, no abnormal nuclear β -catenin localization was identified in any of our cases. The cytoplasmic accumulation of β -catenin without nuclear localization is consistent with the findings of other reports on mammary carcinomas, which suggests that only a small amount of cytoplasmic β -catenin may move to the nucleus, and the subcellular localization of β -catenin might depend on the tumor type. 11, 24, 25 In our study, the ILCs more frequently exhibited the cytoplasmic accumulation or loss of β -catenin, as compared to the IDCs (92% vs 10%; p<0.001). Additionally, the cytoplasmic localization or loss of β -catenin was closely associated with the loss of E-cadherin, and particularly in the ILCs.
The activation of a hormonal receptor-dependent Wnt pathway was recently reported in human cancer cell lines.
26 This previous study showed that the overexpression of ER and PR downregulates or activates the Wnt pathway via direct or indirect interactions. Our results revealed that the ER overexpression increased as the methylation of APC increased. These results are in agreement with those of a previous study, in which ER-negative breast cancers showed lower frequencies of APC methylation. 27 Lin et al. reported that β -catenin is a prognostic marker, while cyclin D1 is one of the molecular targets of the Wnt/β -catenin signaling pathway in human mammary carcinomas.
28 However, there has been controversy over the clinicopathological significance of the β -catenin expression patterns seen on immunohistochemistry. 29 Our results showed that CDH1 or APC methylation was correlated with β -catenin expression, but not with cyclin D1 overexpression. Future molecular analyses must focus on resolving the limitations of immunohistochemical analysis.
The clinical significance of Wnt-1 in human cancers has not yet been well defined. Only one study has thus far been published 14 In the present study, a Wnt-1 expression was detected in 34% of the cases, and this was irrespective of the tumor type. Because our data did not show any significant association among Wnt-1, APC and β -catenin in contrast to the previous study described above, a potentially expanded role of Wnt-1 in mammary oncogenesis needs to be researched and clarified in the future.
Some investigators have reported that the frequency of APC mutation appears to be low in breast cancer, in contrast to colon cancer. 30 In addition, allelic losses, which is another mechanism of gene inactivation, rather than gene mutation itself, could also contribute to the inactivation of APC in breast cancer.
In conclusion, this study demonstrated that CDH1 and APC promoter hypermethylations were common features both in the mammary lobular carcinomas and in the ductal carcinomas. CDH-1 methylation was significantly more common in the ILC than in the IDC, and it was associated with the loss of Ecadherin. Abnormal cytoplasmic accumulation or the loss of β -catenin was correlated with the loss of E-cadherin in mammary lobular carcinomas.
